Moderna Inc. stock (US60770K1034): Bank of America lifts price target after strong run

Bank of America has raised its price target for Moderna Inc. while keeping an underperform rating, following a sharp share price rally in 2026. What is driving sentiment around the vaccine specialist’s stock now?

Moderna Inc. has come back into focus for equity investors after Bank of America Securities raised its price target on the biotech group’s stock from 32 to 34 US?dollars on June 8, 2026, while reiterating an underperform rating according to GuruFocus as of 06/08/2026.

The modestly higher target follows a significant year?to?date rally in Moderna’s share price, with the stock having climbed more than 60% from the beginning of 2026 to trade around the high?40s in recent sessions, according to data compiled by MarketBeat as of 06/09/2026.

As of: 09.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Moderna Inc.
• Sector/industry: Biotechnology, vaccines and therapeutics
• Headquarters/country: Cambridge, Massachusetts, United States
• Core markets: United States, Europe and other global vaccine markets
• Key revenue drivers: Respiratory vaccines, especially COVID?19 products, and other mRNA?based candidates
• Home exchange/listing venue: Nasdaq (ticker: MRNA)
• Trading currency: US?dollar (USD)

Moderna Inc.: core business model

Moderna Inc. is a biotechnology company focused on the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines, with a particular emphasis on infectious diseases and respiratory indications, according to company disclosures on its website and regulatory filings accessible via investor materials such as those referenced by Moderna company information as of 2025.

The firm became widely known to equity markets during the COVID?19 pandemic through its Spikevax vaccine, which generated multi?billion?dollar revenues during the peak vaccination period, as discussed in prior company reports cited by mainstream financial media in 2023 and 2024, including outlets aggregated under Investing.com news as of 2025.

Moderna’s model is based on building a diversified pipeline of mRNA?based products across respiratory viruses, oncology, and rare diseases, with the aim of leveraging a common technology platform to speed development and scale manufacturing once candidates prove successful, according to repeated descriptions in its capital markets presentations and earnings releases referenced in financial coverage during 2024 and early 2025.

A key strategic pillar for the company is to transition from being perceived mainly as a single?product COVID?19 vaccine provider to a broader respiratory and immunotherapy specialist, seeking more stable, recurring revenues from seasonal vaccinations and potential high?value oncology combinations, as industry analysts have frequently highlighted in sector overviews compiled on platforms like MarketBeat as of 2025.

From a structural standpoint, Moderna invests heavily in research and development as well as manufacturing infrastructure, which has led to periods of operating losses after the pandemic revenue peak, but which management has framed as necessary to support multiple commercial launches over the next several years in investor?day materials covered by major US financial media in 2023 and 2024.

Main revenue and product drivers for Moderna Inc.

Even as COVID?19 vaccine volumes have normalized from pandemic peaks, respiratory vaccines remain a core revenue engine for Moderna, with updated formulations and booster campaigns forming a recurring sales base in the United States and key international markets, as described in recent earnings summaries referenced by Zacks earnings overview as of 2025.

In its latest reported quarter, Moderna posted a per?share loss of 1.18 US?dollars, which nonetheless beat the consensus estimate of a loss of 3.02 dollars for the same period, demonstrating how cost discipline and product mix can influence results in a transition phase, according to the earnings summary published by Zacks as of 2025.

Beyond COVID?19 vaccines, investors closely monitor Moderna’s progress in combined respiratory vaccines that target multiple viruses, such as RSV and influenza, because success in these programs could open a large addressable market given the size of seasonal flu and RSV vaccination campaigns in the United States and Europe, according to sector research highlighted across various biotech news round?ups on platforms such as Investing.com as of 2025.

Another important component of Moderna’s future revenue potential is oncology, where the company is developing personalized cancer vaccines in partnership models and proprietary programs, an area that has drawn attention in recent medical conference coverage and which is frequently cited by analysts as a potential multi?year growth driver, as reflected in broader biotech commentary collated on MarketBeat as of 2025.

The mRNA platform also lends itself to rare disease and autoimmune indications, where successful proof?of?concept data could justify premium pricing and long?term treatment regimes, although these programs are still earlier stage relative to the respiratory portfolio, according to company pipeline summaries in investor presentations spanning 2023 to 2025 that have been summarized by major business media.

In addition, Moderna generates revenue from supply agreements with governments and health systems, which can introduce lumpiness depending on timing and size of contracts, a dynamic that has been evident in quarterly revenue swings described in earnings reports and coverage on financial news sites such as those aggregated at Investing.com as of 2024.

Looking forward, the company’s ability to execute multiple product launches, convert clinical trial successes into regulatory approvals, and manage manufacturing capacity will largely determine whether revenues can offset declining legacy COVID?19 sales, a topic that continuously appears in analyst reviews including those referenced by GuruFocus analyst coverage as of 06/08/2026.

Recent rating move and share price performance

The immediate trigger for renewed interest in Moderna’s stock is the rating action by Bank of America Securities, which maintained its underperform recommendation but increased the 12?month price target from 32 to 34 US?dollars, pointing to a slightly less negative stance while still signaling caution, as reported by GuruFocus as of 06/08/2026.

According to that report, the new target represents a level notably below where Moderna’s shares have recently traded, implying that Bank of America sees the current valuation as rich relative to its assumptions, even after accounting for pipeline progress and the possibility of additional product approvals, based on the commentary summarized by GuruFocus as of 06/08/2026.

Year?to?date performance has been robust, with Moderna’s share price rising from around 29.49 dollars at the start of the year to about 47.60 dollars in recent trading, marking a gain of roughly 61%, according to market data compiled by MarketBeat as of 06/09/2026.

Intraday volatility has also been notable, with sessions showing swings of several percentage points as captured in short?term quote overviews from services such as MarketScreener intraday quotes as of 06/09/2026, illustrating how sensitive the stock remains to news on trial results, regulatory milestones, or changes in market sentiment toward biotech and vaccine names.

The strong rally has pushed Moderna’s share price well above some fair?value estimates: GuruFocus, for example, cited a proprietary GF Value of 23.03 US?dollars compared with a contemporaneous share price of 48.55 dollars, implying the stock was trading at a significant premium at the time of analysis, according to GuruFocus valuation data as of 06/08/2026.

For US retail investors, these conflicting signals – strong recent returns but cautious ratings and valuation metrics – underscore the importance of understanding both Moderna’s pipeline prospects and the risks of relying on a technology platform that still needs to prove commercial durability beyond its initial pandemic success, as echoed in multiple analyst commentaries summarized on MarketBeat analyst overview as of 2025.

Insider activity and governance signals

In addition to external analyst views, insider transactions can provide context on management’s perspective, and recent filings show that Moderna’s Chief Legal Officer, Shannon Thyme Klinger, reported activity involving stock options, restricted stock units, and a modest share sale, according to a Form 4 summary on StockTitan Form 4 overview as of 05/2026.

The report states that Klinger acquired a total of 15,269 shares of common stock through option exercises and RSU vesting, and sold 3,471 shares at 50 dollars per share in an open?market transaction executed under a pre?arranged Rule 10b5?1 trading plan, while a separate block of 5,705 shares was withheld to cover tax obligations, according to the same filing summary on StockTitan as of 05/2026.

Form 4 filings are routine disclosure requirements for US?listed companies and do not automatically indicate a change in corporate outlook, but investors sometimes interpret the combination of option exercises and partial share sales as a sign of executives diversifying personal holdings following stock appreciation, a pattern frequently noted in governance research published by corporate?governance specialists and summarized in US capital markets literature.

For Moderna, the mix of acquired and sold shares suggests continued equity exposure for the executive while taking advantage of liquidity following the stock’s rally, a dynamic that some institutional investors monitor as part of their broader assessment of management alignment with shareholders, as discussed in corporate governance commentary across major US financial outlets covering insider activity trends.

Conclusion

Moderna Inc. remains one of the most closely watched US biotech stocks as it shifts from pandemic?era windfalls to a broader mRNA?based portfolio, with respiratory vaccines, oncology candidates, and other pipeline assets in focus for future growth, based on company communications and sector coverage consolidating these themes.

The recent decision by Bank of America Securities to maintain an underperform rating while slightly increasing its price target highlights ongoing valuation concerns after a strong share price rally, as captured in the GuruFocus report, even as other market observers emphasize the strategic value of Moderna’s platform and pipeline diversity.

Insider activity, such as the disclosed transactions by the company’s Chief Legal Officer, adds another piece of information but does not necessarily change the fundamental picture, instead providing context on how executives manage their equity exposure following share price gains.

For US retail investors, Moderna’s story now centers on execution: converting clinical data into approvals, managing post?pandemic vaccine demand, and demonstrating that its mRNA technology can underpin sustainable, multi?product revenue streams, while acknowledging that the stock has already priced in a significant portion of expected progress according to some valuation frameworks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.